Link to this page
Physician Data Query
Preferred Name | isoflurane | |
Synonyms |
Aerrane 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether (SN); 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane Forane Isoflo |
|
Definitions |
A fluorinated ether with general anesthetic and muscle relaxant activities. Although the exact mechanism of action has not been established, inhaled isoflurane, appears to act on the lipid matrix of the neuronal cell membrane, which results in disruption of neuronal transmission. This agent enhances the release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), thereby increasing the activity of the inhibitory neurotransmitter on synaptic transmission. Isoflurane may inhibit glutamatergic excitatory transmission by increasing glutamate re-uptake and it may potentiate glycine receptor activity, which decreases motor function. In addition, isoflurane may alter certain pro- and anti-inflammatory cytokines, including interleukin-6 and -10 (IL-6, IL-10), possibly through the activation of the nuclear factor kappa B (NF-KB) pathway, which may affect immune responses during surgery. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C65978" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C65978" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000752236 |
|
altLabel |
Aerrane 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether (SN); 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane Forane Isoflo
|
|
CAS Registry |
26675-46-7
|
|
cui |
C3651895 C0308273 C0306242 C0022180
|
|
DATE FIRST PUBLISHED |
2013-09-05
|
|
Date last modified |
2013-09-05
|
|
definition |
A fluorinated ether with general anesthetic and muscle relaxant activities. Although the exact mechanism of action has not been established, inhaled isoflurane, appears to act on the lipid matrix of the neuronal cell membrane, which results in disruption of neuronal transmission. This agent enhances the release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), thereby increasing the activity of the inhibitory neurotransmitter on synaptic transmission. Isoflurane may inhibit glutamatergic excitatory transmission by increasing glutamate re-uptake and it may potentiate glycine receptor activity, which decreases motor function. In addition, isoflurane may alter certain pro- and anti-inflammatory cytokines, including interleukin-6 and -10 (IL-6, IL-10), possibly through the activation of the nuclear factor kappa B (NF-KB) pathway, which may affect immune responses during surgery. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C65978" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C65978" NCI Thesaurus)
|
|
LT |
TRD
|
|
NCI ID |
C65978
|
|
notation |
CDR0000752236
|
|
ORIG STY |
Drug/agent
|
|
prefLabel |
isoflurane
|
|
tui |
T109 T121
|
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |